GoldenGolden
Advanced Search
CanSino Biologics

CanSino Biologics

CanSino Biologics (CanSinoBIO) is a bio pharmaceutical company primarily producing vaccines.

Established in Tianjin, China in 2009, CanSino Biologics (CanSinoBIO) has 450 employees. They currently have 15+ vaccines in their pipeline. Some in pre-clinical, some in NDA (new drug application). These include; meningitis, pneumonia, tuberculosis, Ebola virus disease, pertussis, diphtheria, tetanus, shingles etc. Since March of 2019, CanSino Biologics has been listed on the Hong Kong Exchange (HKEx). The annual bulk production capacity of the facilities as of 2020 can reach approximately 70 million to 80 million doses.

COVID-19 response

CanSino Biologics, announced in March 2020 that it was close to testing its novel coronavirus vaccine in a clinical trial in China. CanSino’s approach involves taking part of coronavirus’ genetic code and entwining it with a virus, thereby exposing healthy volunteers to the novel infection and spurring the production of antibodies. CanSino also markets a vaccine for Ebola virus in China.

In April 2020, CanSino Biologics advanced its vaccine candidate candidate, Ad5-nCoV, into Phase II trials (Chinese registration number: ChiCTR2000030906). CanSino Biologics (CanSinoBIO) is collaborating with the National Research Council of Canada (NRC) to advance bioprocessing and clinical development of vaccine candidate against COVID-19, Ad5-nCoV. Ad5-nCoV was co-developed by the Beijing Institute of Biotechnology (BIB) and CanSinoBIO. A genetically engineering replication-defective adenovirus type 5 vector was used to express the SARS-CoV-2 spike protein which is produced in HEK293 cell lines designed and developed at the NRC. As of May 12, 2020, the vaccine is subject to approval by Health Canada for a Clinical Trial Application being filed by CanSinoBIO. As a preparatory step the Government of Canada announced $44 million in funding to support upgrades to NRC facilities in Montreal to ensure readiness for Canadian bioprocessing of potential vaccine candidates.

Timeline

April 19, 2017
CanSino Biologics raises a $65,000,000 series E round from Fortune Capital, Goldstone Financial Group , Gopher Asset Management, Lilly Asia Ventures, QiMing Venture Partners and SDIC Fund Management Company.
April 1, 2016
CanSino Biologics raises a $11,000,000 venture round from QiMing Venture Partners.
November 3, 2015
CanSino Biologics raises a $30,000,000 series C round from Lilly Asia Ventures and Qiming Venture Partners.
September 16, 2013
CanSino Biologics raises a $10,000,000 venture round from Lilly Asia Ventures.
2009
CanSino Biologics was founded by Dongxu QIU, PhD, Tao ZHU, PhD and Xuefeng YU, PhD.

Funding rounds

People

Name
Role
LinkedIn

Dongxu QIU, PhD

Co-Founder/Executive Director/Senior Vice President

Helen Huihua MAO, PhD

Co-Founder/Senior Vice President

Shou Bai CHAO, PhD

Executive Director/Chief Operating Officer

Tao ZHU, PhD

Co-Founder/Executive Director/Chief Scientific Officer

Xuefeng Yu, PhD

Co-Founder/Chairman/Chief Executive Officer

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
May 24, 2021
Forbes India
Critics say the decision will deepen the divisions within the country, where a large section of the society lives under the poverty line
Salman Masood
May 22, 2021
www.nytimes.com
An inoculation push, plagued with limited supplies and red tape, makes doses available to those who can pay for them. In a country with a struggling economy, most can't.
Tom Blackwell
August 4, 2020
nationalpost
Samples of the vaccine candidate have not been approved for shipment to Canada by Chinese customs, one of the researchers confirmed Tuesday
Financial Times
September 24, 2020
nationalpost
Out of 300 candidates, nine are in phase 3 trials, with some hoping for emergency use approval this year
Andrew Dunn
November 9, 2020
Business Insider
There are 45 potential coronavirus vaccines now in human testing, with the frontrunners eyeing potential emergency approval as soon as November.
BS Web Team
July 13, 2020
@bsindia
Coronavirus vaccine latest update: In a major breakthrough, Russia has become the first nation to complete human clinical trials of a Covid-19 vaccine on humans. Catch latest updates on Covid vaccine
Alex Keown
May 22, 2020
BioSpace
A COVID-19 vaccine candidate under development by China's CanSino Biologics is moving forward in development after the company published data supporting its safety in patients.
May 18, 2020
The Rahnuma Daily
Ottawa, May 17 (IANS) The first Canadian clinical trial for a potential COVID-19 vaccine has been officially approved, according to Canadian Prime Minister Justin Trudeau. At his press conference in Ottawa on Saturday, Trudeau said the Canadian Center for Vaccinology at Dalhousie University has been given the green light by Health Canada to begin clinical trials ...

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.